Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Genetic determinants of bone m...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Genetic determinants of bone mineral density loss in Aromatase inhibitors treatment
Bibliographic Details
Main Authors:
Rodriguez-Sanz, M
,
Prieto-Alhambra, D
,
Servitja-Tormo, S
,
Torres-Del-Pliego, E
,
Mellibovsky, L
,
Garrigos, L
,
Garcia-Giralt, N
,
Diez-Perez, A
,
Tusquets, I
,
Nogues, X
Format:
Journal article
Published:
2013
Holdings
Description
Similar Items
Staff View
Similar Items
Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
by: Nogues, X, et al.
Published: (2010)
CTX as an early prediction on bone loss in women on aromatase inhibitors: the B-ABLE cohort study
by: Torres-Del-Pliego, E, et al.
Published: (2013)
Vitamin D repletion and aromatase inhibitor-related bone loss in women non treated with bisphosphonates
by: Prieto-Alhambra, D, et al.
Published: (2011)
Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance
by: Sonia Servitja, et al.
Published: (2015-09-01)
Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
by: Prieto-Alhambra, D, et al.
Published: (2012)